Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard C Becker

Showing results (351-360 of 436) with videos related to

Pageof 44
Sort By:
Journal of the American College of Cardiology|November 28, 2015
Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF TrialMatthew W Sherwood, Christopher C Nessel, Anne S Hellkamp, et al.
Circulation|May 11, 2012
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attackStefan K James, Robert F Storey, Nardev S Khurmi, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|May 14, 2016
Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AFAdam D DeVore, Anne S Hellkamp, Richard C Becker, et al.
Circulation|July 13, 2016
Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation"Jonathan P Piccini, Anne S Hellkamp, Jeffrey B Washam, et al.
Circulation. Heart Failure|June 1, 2013
Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AFSean van Diepen, Anne S Hellkamp, Manesh R Patel, et al.
Journal of the American Heart Association|October 30, 2018
Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF TrialGene R Quinn, Anne S Hellkamp, Graeme J Hankey, et al.
The Journal of Allergy and Clinical Immunology|August 15, 2016
Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamerThomas J Povsic, Monica G Lawrence, A Michael Lincoff, et al.
Circulation|December 18, 2015
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial FibrillationJonathan P Piccini, Anne S Hellkamp, Jeffrey B Washam, et al.
American Heart Journal|April 30, 2017
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromesGregory Ducrocq, Phillip J Schulte, Andrzej Budaj, et al.
Journal of the American Heart Association|May 23, 2024
Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF AnalysisJosephine Harrington, Anne S Hellkamp, Kenneth W Mahaffey, et al.
Pageof 44

Showing results (351-360 of 436) with videos related to

Sort By:
Pageof 44
Journal of the American College of Cardiology|November 28, 2015
Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF TrialMatthew W Sherwood, Christopher C Nessel, Anne S Hellkamp, et al.
Circulation|May 11, 2012
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attackStefan K James, Robert F Storey, Nardev S Khurmi, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|May 14, 2016
Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AFAdam D DeVore, Anne S Hellkamp, Richard C Becker, et al.
Circulation|July 13, 2016
Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation"Jonathan P Piccini, Anne S Hellkamp, Jeffrey B Washam, et al.
Circulation. Heart Failure|June 1, 2013
Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AFSean van Diepen, Anne S Hellkamp, Manesh R Patel, et al.
Journal of the American Heart Association|October 30, 2018
Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF TrialGene R Quinn, Anne S Hellkamp, Graeme J Hankey, et al.
The Journal of Allergy and Clinical Immunology|August 15, 2016
Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamerThomas J Povsic, Monica G Lawrence, A Michael Lincoff, et al.
Circulation|December 18, 2015
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial FibrillationJonathan P Piccini, Anne S Hellkamp, Jeffrey B Washam, et al.
American Heart Journal|April 30, 2017
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromesGregory Ducrocq, Phillip J Schulte, Andrzej Budaj, et al.
Journal of the American Heart Association|May 23, 2024
Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF AnalysisJosephine Harrington, Anne S Hellkamp, Kenneth W Mahaffey, et al.
Pageof 44